BofA lowered the firm’s price target on Ultragenyx (RARE) to $57 from $58 and keeps a Buy rating on the shares after the company reported preliminary 2025 total revenue ahead of guidance in conjunction with the JPMorgan healthcare conference.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx: Better‑Than‑Expected Revenue, Strengthened Liquidity, and Upcoming Pipeline Catalysts Support Maintained Buy Rating
- Ultragenyx provides corporate update, catalysts for 2026
- Ultragenyx reports preliminary FY25 revenue $672M-$674M, consensus $655.9M
- Ultragenyx price target lowered to $50 from $55 at Morgan Stanley
- Ultragenyx: Trial Setback Creates Buying Opportunity as Diversified Pipeline and Commercial Base Support $60 Target